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Doris M. Ponce,1,4 Marissa Lubin,1 Anne Marie Gonzales,1 Courtney Byam,1,2
Deborah Wells,1,2 Rosanna Ferrante,1,2 Glenn Heller,3
Sergio Giralt,1,4 Esperanza B. Papadopoulos,1,4 Nancy A. Kernan,2
Andromachi Scaradavou,2 Juliet N. Barker1,4The inability to obtain additional stem cells is a disadvantage of unrelated donor cord blood transplantation
(CBT). Moreover, in the event of problems with unit shipment, compromised unit quality, thaw mishaps, or
graft failure, the time to secure a back-up graft could be unacceptable. Emergent shipment of 1 to 2 back-up
units that have been previously typed and reserved could overcome this limitation. However, the advantages
of this approach are not established. Therefore, we present our use of back-up units over a 5.5-year period.
Six of 121 CBTrecipients (5%) required back-up unit infusion. Indications included shipment mishaps (n5 2),
poor unit viability (n5 2), significant infusion reaction (n5 1), and graft failure (n5 1). Lack of back-up units
would have caused transplantation delay or infusion of inferior-quality units. Five of the 6 patients achieved
sustained donor engraftment. We demonstrate that back-up units are emergently required in a significant
minority of patients, supporting the incorporation of at least 1 back-up unit in cord blood (CB) selection
algorithms to enhance CBT safety.
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Although cord blood (CB) is increasingly used as
an alternative stem cell source that extends transplant
access to racial and ethnic minorities [1], the inability
to obtain additional cells from the original donor is
a recognized limitation of CB transplantation (CBT).
Graft failure, the traditional indication for a second
infusion, remains a complication of CBT even when
using double-unit grafts, and affects 5% to 10% of
double-unit CBT recipients transplanted for hemato-
logic malignancies [2-4]. However, problems during
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6/j.bbmt.2011.12.588quality on transplant day could trigger the need for
another graft. Lack of immediately available back-up
could threaten timely transplantation or prompt
treatment of graft failure.
At Memorial Sloan-Kettering Cancer Center
(MSKCC), in addition to using double-unit CB grafts
for all CBT recipients as a strategy to augment engraft-
ment [4-7] and potentially enhance graft-versus-
malignancy effects [2,8], we select 1 to 2 back-up
unit(s) for each patient. These are HLA confirmatory
typed, reserved for possible emergency shipment,
and kept at the CB bank until the patient has engrafted.
However, the impact of this practice on patient safety
and the timely completion of transplantation have not
been examined. Therefore, we evaluated our experi-
ence with back-up units in double-unit CBT.METHODS
Patient and Graft Characteristics
This retrospective analysis was conducted in 121
patients who underwent double-unit CBT at MSKCC
between October 1, 2005, and March 31, 2011, for the
treatment of hematologic malignancies. Collection and
analysis of patient/graft demographics and transplanta-
tion outcomes was approved by theHuman Subject In-
stitutional Review Board. Table 1 summarizes patient
Table 1. Patient and Graft Characteristics (n5 121 Patients,
242 Units)
Characteristic
Median age (range) 36 years (0.9-69)
Median weight (range) 66 kg (7-118)
No. diagnosis (%)
Acute leukemia 71 (59)
MDS/CML/other MPD 6 (5)
Lymphoma or CLL 44 (36)
HLA-match (%)*
6/6 11 (5)
5/6 126 (52)
4/6 105 (43)
Median TNC  107/kg (range)*
Larger unit 2.67 (1.42-12.79)
Smaller unit 1.98 (0.91-7.09)
Median CD34+ cell  105/kg (range)*
Larger unit 1.20 (0.26-6.97)
Smaller unit 0.65 (0.08-2.12)
MDS indicates myelodysplastic syndrome; CML, chronic myeloid
leukemia; MPD, myeloproliferative disease; CLL, chronic lymphocytic
leukemia; TNC, total nucleated cell.
*Donor-recipient HLA-match and infused doses refer to the actual graft
received on transplantation day. The second graft for the single patient
who was reinfused for the treatment of graft failure is excluded.
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ing varied according to the patient’s age, diagnosis, re-
mission status, prior therapy, and comorbidities; all
patients received graft-versus-host disease prophylaxis
with a calcineurin-inhibitor plus mycophenolate mofe-
til and granulocyte-colony-stimulating factor as previ-
ously described [3].
Above a cryopreserved total nucleated cell (TNC)
dose of 1.5  107/kg/unit (increased to approximately
2.0  107/kg/unit in 2010), the donor-recipient 4-6/6
HLA-A, HLA-B antigen, and HLA-DRB1 allele
match was given priority while also taking into
account the CB bank of origin [9]. A minimum of 3
to 4 units were selected for confirmatory typing for
each patient. The best 2 were shipped as the graft to
arrive immediately before the pretransplantation con-
ditioning. Back-up units (minimum of 1 and ideally 2
per patient) were typed during initial unit selection
but held in reservation at the CB bank. Only domestic
banks were considered for back-up unit selection due
to the difficulties associated with international ship-
ping at short notice. On transplantation day, each
unit of the graft was assessed for CD341 cell viability
using flow cytometric testing of 7-amino-actinomycin
D staining [10]. Back-up units were released into the
inventory once patients were engrafted.RESULTS
For over 5.5-years, 122 double-unit CBTs were
conducted in 121 patients (including 1 patient who
was transplanted twice). The 244 units were predomi-
nantly from domestic CB banks (n 5 171; 70%). The
cumulative incidence of sustained donor neutrophilengraftment by day 45 was 93% (95% confidence
interval, 89-98) at a median of 24 days (range, 12-43
days) in myeloablative and 10 days (range, 7-36 days)
in nonmyeloablative CBT recipients. Six of the 121
patients (5%, 1 nonmyeloablative and 5 myeloablative
recipients) received 1 to 2 back-up units. Characteris-
tics of patients requiring back-up unit infusion in
chronological order are summarized in Table 2.
Two back-up units were infused on day 34 in
an adult with graft failure after nonmyeloablative
conditioning and without autologous recovery (patient
#1). Notably, the postthaw percentages of viable
CD341 cells in the original units were 74% and 36%.
Back-up units were infused after 4 doses of equine
antithymocyte globulin. This was not successful, and
the patient had autologous recovery 16 days later. Sub-
sequently, analysis of 46 CBT recipients demonstrated
that units with CD341 cell viability\75% were very
unlikely to engraft [10].Therefore,we instituted apolicy
to assess quality as measured by postthaw CD341 cell
viability in all units, and to require at least 1 unit of the
graft to have a CD341 cell viability$75%.
Subsequently, shipment of back-up units was trig-
gered by unacceptable postthaw CD341 cell viability
in 2 children (#3 and #5). In patient #3, both units had
very low viability (48% and 34%). Neither was infused,
and bothwere replacedwith units infused on the follow-
ing day. In patient #5, 1 unit had very low CD341 cell
viability (41%), and the other was borderline (75%).
Asengraftmentwouldhavebeencontingentonaborder-
line viability unit, a decisionwasmade to discard the low
viability unit and replace it with a third that was infused
on day11. Both patients were engrafted uneventfully.
In 2 adult patients (#2 and #6), 1 of the 2 units from
the original graft was compromised during shipment.
In patient #2, the dry shipper was mishandled (opened
prematurely by the courier), and in case #6, the unit ar-
rived fully thawed. Both units were from international
CB banks. A single replacement unit was shipped in
each case; the patients were transplanted as originally
scheduled and engrafted.
Patient #4 had severe bronchospasm at infusion
initiation of the original graft. This unit had been
reconstituted with albumin-dextran dilution. This
unit was discarded while the patient was stabilized.
The second unit of the graft was administered after
washing, a back-up unit was infused uneventfully the
next day, and the patient was engrafted. Subsequently,
this patient had a similar reaction to platelets.DISCUSSION
CB is processed up to 48 hours after birth, cryopre-
served until transplantation, shipped, stored, thawed,
and infused. Problems at any of these steps could
render the patient in need of an urgent alternative
stem cell source. Given the inability to return to the
Table 2. Summary of Patients Requiring Shipment of One or More Back-up Units
Case
HLA-match and pre-thaw TNC ( 107/kg)
CD34+ cell viability
Back-up unit indication OutcomeOriginal units* Back-up unit(s)
#1 1a: 4/6 & 2.7
CD34+: 74%
2a: 4/6 & 2.1
CD34+: 91%
Graft failure Autologous recovery
1b: 4/6 & 2.0
CD34+: 36%
2b: 4/6 & 1.8
CD34+: 97%
#2 1a: 5/6 & 2.1
CD34+: NE†
2a: 4/6 & 2.9
CD34+: 85%
1a mishandled (discarded) 2a engrafted
1b: 4/6 & 3.3
CD34+: 68%
#3 1a: 5/6 & 2.6
CD34+: 48%
2a: 5/6 & 2.0
CD34+: 97%
Low viability of 1a and 1b 2a engrafted
1b: 5/6 & 2.2
CD34+: 34%
2b: 4/6 & 4.1
CD34+: 96%
#4 1a: 4/6 & 3.5
CD34+: 96%
2a: 4/6 & 3
CD34+: 96%
Bronchospasm to 1b (discarded) 2a engrafted
1b: 4/6 & 2.6
CD34+: 95%
#5 1a: 5/6 & 4.8
CD34+: 41%
2a: 5/6 & 2.0
CD34+: 93%
Low viability of 1a; borderline viability of 1b 1b engrafted
1b: 4/6‡ & 1.9
CD34+: 75%
#6 1a: 4/6 & 2.9
CD34+: 93%
2a: 4/6 & 3.3
CD34+: 74%
1b arrived thawed (discarded) 1a engrafted
1b: 4/6 & 3.0
CD34+: NE†
TNC indicates total nucleated cell; NE, nonevaluable.
*Of the original graft, 1a and 1b reflects the order of unit selection and not the order of infusion; 7 units were domestic and 5 were international.
†NE: units were not tested.
‡This 4/6 unit was originally chosen as unit 1b of the graft over the 5/6 back-up unit as it was homozygous (and thus had nomismatches in the direction of
rejection) given the reported advantages of such units [16].
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could be compromised if an emergency back-up
strategy is not in place. Therefore, we have elected to
identify and reserve 1 to 2 back-up unit(s) for all pa-
tients. We found that using our best clinical judgment,
5% of our patients required back-up unit shipment in
a 5.5-year period.
We have hypothesized that double-unit CBT may
be effective in part by increasing the chance that at
least 1 unit of good quality, and thus engraftment po-
tential, is infused [10]. Scaradavou et al. [10] reported
that units with a CD341 cell viability \75% were
very unlikely to engraft, and Avery et al. [4] confirmed
that low CD341 cell viability was associated with an
increased graft failure risk. Unfortunately, borderline
or low CD341 cell viability postthaw is not a rare
event.We and others have previously detected variable
unit quality between units and banks [4,11,12], and
that unit quality cannot be assessed until thaw is
a major challenge for transplantation centers. After
the graft failure in the first patient of this report, we
instituted rapid testing at thaw to ensure infusion of
at least 1 unit with CD341 cell viability $75%.
CD341 cell viability, or a similar potency assay with
same-day results [13], is currently the only practical
method to evaluate CB quality. Hopefully, improved
processing and cryopreservation technology, and opti-
mization of preshipment-attached segment potencytesting [14], will eliminate the risk of poor-quality
units on transplantation day in the future. Until then,
however, having available back-up offers an immediate
solution if graft compromise is detected at thaw.
Problems during unit transportation occurred in
2 cases. Other centers have also reported accidents
during unit handling, such as bag rupture during
centrifugation (J. Barker, personal communication,
2011) or shipment of mislabeled units [15]. In such
instances, timely arrival of back-up units can prevent
transplantation delay. We also encountered 1 patient
with a serious infusion reaction. In our experience,
these are quite uncommon, even with unwashed units
[6]. Although the unit could have been stored while
the patient was stabilized, we elected to infuse a fresh
back-up unit the next day.
One striking finding of our report is that graft
failure was the back-up shipment indication in only 1
case. Five additional graft failure cases occurred during
the study period, all in myeloablative conditioning
recipients. In these patients, the development of
life-threatening organ failure precluded back-up unit
infusion. Also noteworthy is that the graft failure
patient treated with a second CBT did not engraft,
and the patient ultimately had autologous recovery.
Whereas this may have been due to inadequate immu-
nosuppression from the nonmyeloablative condition-
ing and sensitization from the first infusion, this case
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cation facilitates early stem cell reinfusion.
Our back-up policy coupled with testing of unit
quality at thaw can facilitate timely delivery of
a high-quality CB product. Although we could have
proceeded with single-unit CBT, 2 units were admin-
istered due to the apparent engraftment advantage and
relapse protection of double-unit CBT [2,8]. We
acknowledge that double-unit grafts are only needed
if double-unit CBT is proven to be superior to
single-unit transplantation. However, the principle
that a back-up graft may be required is valid regardless
of whether single or double-unit CBT is performed. In
fact, it is likely that back-up units will be needed more
frequently in single-unit CBT given the risk that com-
promised quality will be higher if the graft consists of
only 1 unit. Furthermore, although it could also be
argued that a haplo-identical donor could be used in
an emergency, the shipment of previously reserved
domestic CB units can be achieved within 24 hours,
which is considerably faster than the work-up and
mobilization of a related donor.
Importantly, although there is a substantial cost to
back-up graft shipment, the reservation of 1 to 2 units
adds safety without adding any cost as most patients
will have more than 1 to 2 units confirmatory typed,
and the best units of those not selected for the graft
can be reserved until engraftment. This approach
adds little additional coordinator effort and facilitates
efficient management of emergency situations. In the
United States, the challenges associated with interna-
tional shipping means that it is only practical to reserve
domestic units as back-ups. However, with the
enlarging inventory, most patients will have a satisfac-
tory domestic unit. Therefore, we propose the imple-
mentation of rapid testing of unit quality and routine
reservation of at least 1 back-up unit as a strategy to
ensure timely delivery of an optimal CB product, and
thus optimize the safety of CBT.ACKNOWLEDGMENTS
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